Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist. It works by mimicking two naturally occurring gut hormones — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) — that are released after eating.
Together, these hormones:
- Signal to your brain that you are full, reducing appetite
- Slow gastric emptying, helping you feel satisfied for longer
- Improve blood sugar regulation
Mounjaro is administered as a once-weekly subcutaneous injection. It is prescribed as part of a structured treatment programme and is most effective when combined with dietary changes and increased physical activity.